Literature DB >> 32524330

Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.

Nadeem Qureshi1, Brittany Dutton2, Stephen Weng2, Christina Sheehan2, Wendy Chorley3, John F R Robertson4, Denise Kendrick2, Joe Kai2.   

Abstract

Family history of breast cancer is a key risk factor, accounting for up to 10% of cancers. We evaluated the proactive assessment of familial breast cancer (FBC) risk in primary care. Eligible women (30 to 60 years) were recruited from eight English general practices. Practices were trained on FBC risk assessment. In four randomly-assigned practices, women were invited to complete a validated, postal family history questionnaire, which practice staff inputted into decision support software to determine cancer risk. Those with increased risk were offered specialist referral. Usual care was observed in the other four practices. In intervention practices, 1127/7012 women (16.1%) returned family history questionnaires, comprising 1105 (98%) self-reported white ethnicity and 446 (39.6%) educated to University undergraduate or equivalent qualification, with 119 (10.6%) identified at increased breast cancer risk and offered referral. Sixty-seven (56%) women recommended referral were less than 50 years old. From 66 women attending specialists, 26 (39.4%) were confirmed to have high risk and recommended annual surveillance (40-60 years) and surgical prevention; while 30 (45.5%) were confirmed at moderate risk, with 19 offered annual surveillance (40-50 years). The remaining 10 (15.2%) managed in primary care. None were recommended chemoprevention. In usual care practices, only ten women consulted with concerns about breast cancer family history. This study demonstrated proactive risk assessment in primary care enables accurate identification of women, including many younger women, at increased risk of breast cancer. To improve generalisability across the population, more active methods of engagement need to be explored.Trial registration: CRUK Clinical Trials Database 11779.

Entities:  

Keywords:  Breast cancer; Decision support; Family history; Medical genetics; Primary health care; Risk assessment

Year:  2020        PMID: 32524330      PMCID: PMC7870768          DOI: 10.1007/s10689-020-00188-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  36 in total

1.  Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer.

Authors:  F Eisinger; G Geller; W Burke; N A Holtzman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

Review 2.  Familial breast cancer.

Authors:  F Lalloo; D G Evans
Journal:  Clin Genet       Date:  2012-04-13       Impact factor: 4.438

3.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Authors:  Mieke Kriege; Cecile T M Brekelmans; Carla Boetes; Peter E Besnard; Harmine M Zonderland; Inge Marie Obdeijn; Radu A Manoliu; Theo Kok; Hans Peterse; Madeleine M A Tilanus-Linthorst; Sara H Muller; Sybren Meijer; Jan C Oosterwijk; Louk V A M Beex; Rob A E M Tollenaar; Harry J de Koning; Emiel J T Rutgers; Jan G M Klijn
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

4.  Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging.

Authors:  Srila Samphao; Amanda J Wheeler; Elizabeth Rafferty; James S Michaelson; Michelle C Specht; Michele A Gadd; Kevin S Hughes; Barbara L Smith
Journal:  Am J Surg       Date:  2009-10       Impact factor: 2.565

Review 5.  [Revised practice guideline 'Screening and diagnosis of breast cancer'].

Authors:  H M Zonderland; M K Tuut; G J den Heeten; C J Asperen; G H de Bock; E J Th Rutqers; P J Westenend; G M Hoeksma Smit; J Benraadt
Journal:  Ned Tijdschr Geneeskd       Date:  2008-10-25

6.  Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.

Authors: 
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

7.  Dealing with family history of breast cancer: something new, something old.

Authors:  Nadeem Qureshi; Norma O'Flynn; Gareth Evans
Journal:  Br J Gen Pract       Date:  2014-01       Impact factor: 5.386

8.  Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention.

Authors:  D Gareth Evans; Adam R Brentnall; Michelle Harvie; Sarah Dawe; Jamie C Sergeant; Paula Stavrinos; Susan Astley; Mary Wilson; John Ainsworth; Jack Cuzick; Iain Buchan; Louise S Donnelly; Anthony Howell
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-21

9.  Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey.

Authors:  Maren T Scheuner; Timothy S McNeel; Andrew N Freedman
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

10.  Engagement barriers and service inequities in the NHS Breast Screening Programme: Views from British-Pakistani women.

Authors:  Victoria G Woof; Helen Ruane; Fiona Ulph; David P French; Nadeem Qureshi; Nasaim Khan; D Gareth Evans; Louise S Donnelly
Journal:  J Med Screen       Date:  2019-12-02       Impact factor: 2.136

View more
  2 in total

1.  Transforming the 2-week wait (2WW) pathway: management of breast pain in primary care.

Authors:  Mohamed Jahan; Thilan Bartholomeuz; Nikki Milburn; Veronica Rogers; Mark Sibbering; John Robertson
Journal:  BMJ Open Qual       Date:  2022-03

2.  Implementing Risk-Stratified Breast Screening in England: An Agenda Setting Meeting.

Authors:  Lorna McWilliams; D Gareth Evans; Katherine Payne; Fiona Harrison; Anthony Howell; Sacha J Howell; David P French
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.